Global Cancer Monoclonal Antibodies Market 2017-2021
About Cancer Monoclonal Antibodies
The mAbs, which are produced by genetic engineering, target antigens in cells, tissues, and organs. They are used in clinical applications to treat diseases with excellent efficacy and minimal side effects. Their MOA, absence of generic pathway, and therapeutic applications distinguish them from other targeted therapeutics.
Technavio’s analysts forecast the global cancer monoclonal antibodies market to grow at a CAGR of 10.86% during the period 2017-2021.
Covered in this report
The report covers the present scenario and the growth prospects of the global cancer monoclonal antibodies market for 2017-2021. To calculate the market size, the report considers the revenue generated from the sales of branded cancer mAbs and biosimilars used to treat cancer. It also considers the revenues to be generated from the sales of drugs that are expected to be launched into the market along with the decline in revenues from the patent expiries of the marketed drugs during the forecast period.The market is divided into the following segments based on geography:
Technavio Announces the Publication of its Research Report – Global Cancer Monoclonal Antibodies Market 2017-2021
Technavio recognizes the following companies as the key players in the global cancer monoclonal antibodies market: F. Hoffmann-La Roche, Amgen, Bristol-Myers Squibb, and Takeda Pharmaceuticals.
Other Prominent Vendors in the market are: AbbVie, ADC Therapeutics, Agensys, Argos Therapeutics, Astellas Pharma, AstraZeneca, Bayer, Biogen, Biotech Pharmaceutical, BioGenomics, Boehringer Ingelheim, Celldex Therapeutics, Chugai Pharmaceutical, CTI BioPharma, Daiichi Sankyo, Eli Lilly, Fortress Biotech, Genmab, Immunomedics, Intas Pharmaceuticals, Janssen Biotech, Kyowa Hakko Kirin, Merck, MedImmune, Morphotek, Neovii Biotech, Novartis, OncoMed Pharmaceuticals, Pfizer, Sanofi, Seattle Genetics, TG Therapeutics, and Xbiotech.
Commenting on the report, an analyst from Technavio’s team said: “The latest trend gaining momentum in the market is emergence of targeted and combination therapies. Targeted and combination therapies are being increasingly developed for the treatment of cancers and inflammatory diseases. These therapies, which exploit the surface markers or properties of diseased or infected cells, cause fewer adverse side effects than conventional non-targeted therapies.”
According to the report, one of the major drivers for this market is increase in demand for ADCs. Antibodies are increasingly becoming the preferred choice to treat diseases such as respiratory, oncology, and inflammatory diseases. Understanding diseases at a molecular level increases the development and use of antibodies. The use of ADCs, including radioimmunotherapy and antibody-directed enzyme prodrug therapy, is growing. The increasing use of these antibodies in drug development increases revenue generation in the global next-generation biologics market, thereby contributing to the cancer mAbs market growth.
Further, the report states that one of the major factors hindering the growth of this market is complicated regulatory framework. Gaining regulatory approval is often difficult, unpredictable, and subjective. Biologics products must undergo a broad range of stringent regulations before approval and commercialization. Currently, the US FDA has approved very few products for stem cell therapy. However, there are several transplant centers running in the region that uses unapproved cell therapies.
F. Hoffmann-La Roche, Amgen, Bristol-Myers Squibb, Takeda Pharmaceuticals, AbbVie, ADC Therapeutics, Agensys, Argos Therapeutics, Astellas Pharma, AstraZeneca, Bayer, Biogen, Biotech Pharmaceutical, BioGenomics, Boehringer Ingelheim, Celldex Therapeutics, Chugai Pharmaceutical, CTI BioPharma, Daiichi Sankyo, Eli Lilly, Fortress Biotech, Genmab, Immunomedics, Intas Pharmaceuticals, Janssen Biotech, Kyowa Hakko Kirin, Merck, MedImmune, Morphotek, Neovii Biotech, Novartis, OncoMed Pharmaceuticals, Pfizer, Sanofi, Seattle Genetics, TG Therapeutics, and Xbiotech.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook